Patents by Inventor Gideon Gross

Gideon Gross has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20180263777
    Abstract: Apparatuses and devices usable for annuloplasty are provided. These can include a plurality of helical tissue anchors and an annuloplasty structure for placement on a heart valve annulus. The annuloplasty structure can include a plurality of compressible or adjustable subunits, and a plurality of anchor mounts alternately disposed with respect to the plurality of compressible/adjustable subunits. The anchor mounts are coupleable to the helical anchors and can define a path for passage therethrough of a respective helical tissue anchor. The apparatuses and devices can be independently adjustable and can be adjustable for treating various sizes of patient annuli. Other embodiments are also described.
    Type: Application
    Filed: May 18, 2018
    Publication date: September 20, 2018
    Inventors: Amir Gross, Iftah Beinart, Eran Miller, Oz Cabiri, Eliahu Eliachar, Nir Lilach, Ram Grossfeld, Dmitry Golom, Gideon Meyer-Brodnitz, Arnon Mosaiuf
  • Publication number: 20180263776
    Abstract: Apparatuses and devices usable for annuloplasty are provided. These can include a plurality of tissue anchors and an annuloplasty structure for placement on a heart valve annulus. The annuloplasty structure can include a plurality of compressible or adjustable subunits, and a plurality of anchor mounts alternately disposed with respect to the plurality of compressible/adjustable subunits. The anchor mounts are coupleable to the tissue anchors and can define a path for passage therethrough of a respective tissue anchor. The apparatuses and devices can be independently adjustable and can be adjustable for treating various sizes of patient annuli. Other embodiments are also described.
    Type: Application
    Filed: May 18, 2018
    Publication date: September 20, 2018
    Inventors: Amir Gross, Iftah Beinart, Eran Miller, Oz Cabiri, Eliahu Eliachar, Nir Lilach, Ram Grossfeld, Dmitry Golom, Gideon Meyer-Brodnitz, Arnon Mosaiuf
  • Patent number: 8211422
    Abstract: Chimeric receptor genes suitable for endowing lymphocytes with antibody-type specificity include a first gene segment encoding a single-chain Fv domain of a specific antibody and a second gene segment encoding all or part of the transmembrane and cytoplasmic domains, and optionally the extracellular domain, of an immune cell-triggering molecule. The chimeric receptor gene, when transfected to immune cells, expresses the antibody-recognition site and the immune cell-triggering moiety into one continuous chain. The transformed lymphocytes are useful in therapeutic treatment methods.
    Type: Grant
    Filed: October 24, 1995
    Date of Patent: July 3, 2012
    Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, Yeda Research and Development Co., Ltd.
    Inventors: Zelig Eshhar, Daniel Schindler, Tova Waks, Gideon Gross, Steven A. Rosenberg, Patrick Hwu
  • Publication number: 20120093842
    Abstract: Chimeric receptor genes suitable for endowing lymphocytes with antibody-type specificity include a first gene segment encoding a single-chain Fv domain of a specific antibody and a second gene segment encoding all or part of the transmembrane and cytoplasmic domains, and optionally the extracellular domain, of an immune cell-triggering molecule. The chimeric receptor gene, when transfected to immune cells, expresses the antibody-recognition site and the immune cell-triggering moiety into one continuous chain. The transformed lymphocytes are useful in therapeutic treatment methods.
    Type: Application
    Filed: October 26, 2011
    Publication date: April 19, 2012
    Applicants: The United States of America, as represented by the Secretary, Dept. of Health & Human Service, YEDA RESEARCH AND DEVELOPMENT CO., LTD.
    Inventors: Zelig Eshhar, Daniel Schindler, Tova Waks, Gideon Gross, Steven A. Rosenberg, Patrick Hwu
  • Patent number: 7741465
    Abstract: Chimeric receptor genes suitable for endowing lymphocytes with antibody-type specificity include a first gene segment encoding a single-chain Fv domain of a specific antibody and a second gene segment encoding all or part of the transmembrane and cytoplasmic domains, and optionally the extracellular domain, of an immune cell-triggering molecule. The chimeric receptor gene, when transfected to immune cells, expresses the antibody-recognition site and the immune cell-triggering moiety into one continuous chain. The transformed lymphocytes are useful in therapeutic treatment methods.
    Type: Grant
    Filed: July 2, 1993
    Date of Patent: June 22, 2010
    Inventors: Zelig Eshhar, Daniel Schindler, Tova Waks, Gideon Gross
  • Publication number: 20080286312
    Abstract: The invention provides a polynucleotide comprising a sequence encoding a polypeptide that is capable of high level presentation of antigenic peptides on antigen-presenting cells, wherein the polypeptide comprises a ?2-microglobulin molecule that is linked through its carboxyl terminal to a bridge peptide which spans the whole distance to the cell membrane, said bridge peptide being linked to a polypeptide stretch consisting of the full or partial transmembrane and/or cytoplasmic domains selected from the group consisting of a toll-like receptor (TLR) polypeptide, a CD40 polypeptide, and TLR and CD40 polypeptides fused in tandem, that allows the anchorage of the ?2-microglobulin molecule to the cell membrane, and through its amino terminal to at least one antigenic peptide comprising an MHC class I epitope, wherein said antigenic peptide is preferably derived from a tumor-associated antigen or from a pathogenic antigen.
    Type: Application
    Filed: October 3, 2006
    Publication date: November 20, 2008
    Applicant: Gavish-Galilee Bio Applications Ltd.
    Inventors: Gideon Gross, Alon Margalit
  • Patent number: 7319143
    Abstract: The invention provides DNA molecules encoding a chimeric polypeptide comprising (a) a component of a MHC molecule capable of association on a cell surface with an endogenous MHC molecule component of the same class, and (b) an intracellular region of a signal transduction element capable of activating T cells. Component (a) may be a monomorphic component and is preferably beta 2-microglobulin, or a polymorphic class I or class II component. The signal transduction element (b) capable of activating T cells may be a component of T-cell receptor CD3, preferably the CD3 zeta (zeta) polypeptide, a B cell receptor polypeptide or an Fc receptor polypeptide. Immune cells such as a CTLs expressing said chimeric MHC molecules specifically eliminate or inactivate harmful T cells and are useful for treating graft rejection and autoimmune diseases.
    Type: Grant
    Filed: May 31, 2001
    Date of Patent: January 15, 2008
    Assignee: Gavish-Galilee Bio Application Ltd.
    Inventors: Gideon Gross, Alon Margalit
  • Publication number: 20060003315
    Abstract: The invention provides a polynucleotide comprising a sequence encoding a polypeptide comprising a beta2-microglobulin molecule linked through its carboxyl terminal to a polypeptide stretch that allows the anchorage of the beta2-microglobulin molecule to the cell membrane, and through its amino terminal to at least one antigenic peptide comprising a MHC class I epitope, wherein said antigenic peptide is not related to an autoimmune disease and is preferably derived from a tumor-associated antigen or from a pathogenic antigen. Antigen presenting cells, and DNA and cellular vaccines for treatment of cancer and infectious diseases, are also provided.
    Type: Application
    Filed: June 12, 2003
    Publication date: January 5, 2006
    Applicant: Gavish-Galilee Bio Applications Ltd.
    Inventors: Gideon Gross, Alon Margalit
  • Publication number: 20040137562
    Abstract: The invention provides DNA molecules encoding a chimeric polypeptide comprising (a) a component of a MHC molecule capable of association on a cell surface with an endogenous MHC molecule component of the same class, and (b) an intracellular region of a signal transduction element capable of activating T cells. Component (a) may be a monomorphic component and is preferably beta 2-microglobulin, or a polymorphic class I or class II component. The signal transduction element (b) capable of activating T cells may be a component of T-cell receptor CD3, preferably the CD3 zeta (zeta) polypeptide, a B cell receptor polypeptide or an Fc receptor polypeptide. Immune cells such as a CTLs expressing said chimeric MHC molecules specifically eliminate or inactivate harmful T cells and are useful for treating graft rejection and autoimmune diseases.
    Type: Application
    Filed: December 2, 2002
    Publication date: July 15, 2004
    Inventors: Gideon Gross, Alon Margalit
  • Publication number: 20040110922
    Abstract: Chimeric proteins are provided having binding specificity for at least two different sites, at least one site being on the HIV envelope glycoprotein gp120 and the other bite being either on said gp120 protein or on the extracellular portion of human CD4, said chimeric protein comprising: (a) a first binding region comprising a soluble extracellular portion of human CD4; (b) a second binding region comprising a variable region of an antibody heavy chain, preferably VH3; (c) a linker that connects (a) and (b); and, optionally, a portion of a constant region of an immunoglobulin chain. The chimeric proteins are useful for prevention and treatment of HIV infection.
    Type: Application
    Filed: July 22, 2003
    Publication date: June 10, 2004
    Inventors: Gideon Gross, Ronit Meyuhas
  • Publication number: 20020137697
    Abstract: Chimeric receptor genes suitable for endowing lymphocytes with antibody-type specificity include a first gene segment encoding a single-chain Fv domain of a specific antibody and a second gene segment encoding all or part of the transmembrane and cytoplasmic domains, and optionally the extracellular domain, of an immune cell-triggering molecule. The chimeric receptor gene, when transfected to immune cells, expresses the antibody-recognition site and the immune cell-triggering moiety into one continuous chain. The transformed lymphocytes are useful in therapeutic treatment methods.
    Type: Application
    Filed: October 24, 1995
    Publication date: September 26, 2002
    Inventors: ZELIG A. ESHHAR, DANIEL SCHINDLER, TOVA WAKS, GIDEON GROSS, STEVEN A. ROSENBERG, PATRICK HWU
  • Patent number: 5912172
    Abstract: There are produced recombinant gene pairs which endow mononuclear cells, mainly various lymphocyte type cells, with antibody-type specificity. In specific gene pairs the rearranged gene pairs code for a binding site of an antibody molecule from the same species, of the T-cell receptor gene, or another species. Gene pairs of the invention code, for example, for antibodies specific towards tumor-specific antigens, viral antigens, modified self antigens, bacterial or fungal antigens, autoimmune type disease antigens and the like. The invention further relates to expression vectors for the effective transfection of such cell types comprising such a recombinant gene pair, to methods for producing same and to pharmaceutical compositions comprising as active ingredient an effective quantity of lymphocytes transfected with such gene pairs.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: June 15, 1999
    Assignee: Yeda Research and Development Co. Ltd.
    Inventors: Zelig Eshhar, Gideon Gross, Tova Waks
  • Patent number: 5906936
    Abstract: There are produced recombinant gene pairs which endow mononuclear cells, mainly various lymphocyte type cells, with antibody-type specificity. In specific gene pairs the rearranged gene pairs code for a binding site of an antibody molecule from the same species, of the T-cell receptor gene, or another species. Gene pairs of the invention code, for example, for antibodies specific towards tumor-specific antigens, viral antigens, modified self antigens, bacterial or fungal antigens, autoimmune type disease antigens and the like. The invention further relates to expression vectors for the effective transfection of such cell types comprising such a recombinant gene pair, to methods for producing same and to pharmaceutical compositions comprising as active ingredient an effective quantity of lymphocytes transfected with such gene pairs.
    Type: Grant
    Filed: May 4, 1993
    Date of Patent: May 25, 1999
    Assignee: Yeda Research and Development Co. Ltd.
    Inventors: Zelig Eshhar, Gideon Gross, Tova Waks